Alpha 2.0
Login Register
» Authors » Marie Sebert

Marie Sebert

Explore the profile of Marie Sebert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 57
Citations 957
Followers 0
Related Specialties
Hematology
Oncology
Cell Biology
Top 10 Co-Authors
Lionel Ades
Pierre Fenaux
Emmanuelle Clappier
Emmanuel Raffoux
Raphael Itzykson
Etienne Lengline
Jean Soulier
Nicolas Boissel
Herve Dombret
Rathana Kim
Published In
Haematologica
Blood
Leukemia
Leuk Res
Br J Haematol
Affiliations
Soon will be listed here.
Recent Articles
1.
Very long-term remission with azacitidine in VEXAS syndrome
Zhao L, Jachiet V, Kosmider O, Larcher L, Clappier E, Sebert M, et al.
Haematologica . 2025 Jan; PMID: 39882650
Not available.
2.
Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemia
Pacchiardi K, de Marcellus V, Huynh T, Fodil S, Kim R, Bello R, et al.
Cytometry B Clin Cytom . 2024 Nov; 108(1):86-94. PMID: 39600238
BH3 profiling can assess global mitochondrial priming and dependence of leukemic cells on specific BH3 anti-apoptotic proteins such as BCL-2. In acute myeloid leukemia (AML), proof-of-concept prognostic studies have been...
3.
Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia
Puisset F, Raffoux E, Ades L, Huynh T, Itzykson R, Bouscary D, et al.
Haematologica . 2024 Oct; PMID: 39415682
Not available.
4.
Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule
Kelly L, Rutter J, Lin K, Ling F, Duchmann M, Latour E, et al.
Nat Cancer . 2024 May; 5(7):1082-1101. PMID: 38816660
Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in nonmalignant tissues. This obstacle can be minimized by targeting cancer...
5.
Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen
Robin M, Nibourel O, Tournaire M, Michonneau D, Preudhomme C, Verbanck M, et al.
Bone Marrow Transplant . 2024 May; 59(9):1309-1312. PMID: 38783124
No abstract available.
6.
Cutaneous clonal mature plasmacytoid dendritic cell dermatosis in patients with myeloid neoplasms
Mahevas T, Osio A, Larcher L, Clappier E, Kempf W, Ades L, et al.
Blood Adv . 2024 Apr; 8(12):3293-3298. PMID: 38621250
No abstract available.
7.
Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission
Urbino I, Lengline E, Rabian F, Cerrano M, Kim R, Chevillon F, et al.
Blood Adv . 2024 Mar; 8(10):2405-2409. PMID: 38507689
No abstract available.
8.
Germline CHEK2 mutations in patients with myeloid neoplasms
Freiman L, Larcher L, Tueur G, Vasquez N, Da Costa M, Duchmann M, et al.
Leukemia . 2024 Feb; 38(4):908-911. PMID: 38378842
No abstract available.
9.
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
Sebert M, Freiman L, Chaffaut C, Guerci A, Peterlin P, Thepot S, et al.
Leukemia . 2024 Feb; 38(4):918-922. PMID: 38368440
No abstract available.
10.
Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia
Urbino I, Lengline E, Valade S, Cerrano M, Sebert M, Raffoux E, et al.
Crit Care . 2024 Jan; 28(1):14. PMID: 38183144
No abstract available.